Every challenge. Every day. Every voice.

Explore the connections across the drug discovery and development continuum- linking patients with their life-saving drugs.


Ginger's voice was her lifeblood. For over 35 years, Ginger was a professional singer in the Chicago area, but everything changed the day she was diagnosed with Stage IV non-small cell lung cancer (NSCLC).

By the numbers


people living with lung cancer

~ 85%

of US lung cancer patients have NSCLC


AstraZeneca (AZ) is a global biopharmaceutical company whose innovative medicines are used by millions of patients worldwide. AstraZeneca and Charles River extended our initial three-year partnership into 2020. The new agreement solidifies Charles RIver as AZ's preferred strategic partner for outsourced, regulated, safety assessment and development DMPK (drug metabolism and pharmacokinetics).

By the numbers

> 100

countries within global reach


goal to develop six new cancer drugs


Osimertinib is designed to treat patients like Ginger with metastatic EGFR T790M mutation-positive non-small cell lung cancer who progressed on or after EGFR TKI therapy.

It was brought to market in November 2015 and granted Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval status by the FDA – progressing from clinical trials to market in ~2.5 years.

By the numbers

~ 2.5

years from clinical trials to market

10 - 20%

of NSCLCs are EGFR mutation-positive

Safety Assessment

Safety Assessment is a critical step along the drug discovery and development continuum. Between 2013-2015, Charles River performed toxicology studies on osimertinib to meet an accelerated FDA timeline. Charles River's work in preclinical development and clinical support services were vital to ensuring the drug's dosage levels would be safe for patients like Ginger.

By the numbers

> 5,000


> 100



global sites


Find out more about Ginger’s story and lung cancer drug development.

Getting Personal with Your Tumor

For lung cancer patients like Ginger Tam, targeted therapies demonstrate the potential of precision medicine.

Learn More
Featured Story:
Lung Cancer Alliance Collaboration

Charles River is proud to partner with Lung Cancer Alliance with our Every Voice campaign.

Learn More
Remembering Ginger Tam

Her legacy is one of unwavering commitment to fellow survivors by making sure their voices were heard. Ginger made an indelible mark on the lung cancer community and will always be remembered.

Learn More